Treatment with derazantinib produced an ORR of 20.7%, a DCR of 82.8%, and a mPFS of 5.7 months in previously treated patients with advanced iCCA and FGFR2 fusions (NCT01752920) [135]. The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.